Drug Profile
Research programme: adenosine A3 modulators - OSI Pharmaceuticals
Latest Information Update: 20 Jul 2006
Price :
$50
*
At a glance
- Originator OSI Pharmaceuticals
- Class
- Mechanism of Action Adenosine A3 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glaucoma
Most Recent Events
- 31 Dec 2005 No development reported - Preclinical for Glaucoma in USA (unspecified route)
- 26 Jun 2002 This programme is still in active development
- 25 Feb 2000 Preclinical development for Glaucoma in USA (Unknown route)